Article
“The anti-angiogenic compound axitinib demonstrates low toxicity and anti-tumoral effects against medulloblastoma”
2020-09-19
Abstract excerpt
<h4>ABSTRACT</h4> Evolution of medulloblastoma (MB) treatments has increased the 5-year overall survival of to more than 70%. However, an increasing number of survivors face severe long-term adverse effects and associated morbidity due to multimodal treatments particularly harsh for the younger patients. Chemotherapeutic compounds inducing less adverse effects are key to improving the care of MB patients. The pre...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9b6167ab-2b46-57bd-9532-da94ff77bb3c
- DOI
- 10.1101/2020.09.18.301028